Use of Intravitreal Aflibercept Injection for Neovascular Glaucoma
Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
This 52 week study will assess the use of intravitreal aflibercept injections in patients
with neovascular glaucoma (NVG) compared to standard of care panretinal photocoagulation.
The investigators hypothesize that the neovascularization of the iris and angle present in
neovascular glaucoma will resolve more quickly in eye treated with intravitreal aflibercept
injection alone and result in increased comfort and preservation of visual field as compared
to current standard of care utilizing pan-retinal photocoagulation. The advantages to
intravitreal aflibercept injection use could include resolution of NVI/NVA
(neovascularization of the iris/neovascularization of the angle) leading to quicker pain
relief and quicker lowering of IOP (intraocular pressure).